Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Celldex Therapeutics buy Morgan Stanley

Start price
€18.40
20.03.25 / 50%
Target price
€42.18
20.03.26
Performance (%)
42.39%
End price
€26.20
21.03.26
Summary
This prediction ended on 21.03.26 with a price of €26.20. The BUY prediction by Morgan_Stanley for Celldex Therapeutics saw massive gains of 42.39%. Morgan_Stanley has a follow-up prediction for Celldex Therapeutics where he still thinks Celldex Therapeutics is a Buy. Morgan_Stanley has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y
Celldex Therapeutics -1.538% -1.538% 39.891%
iShares Core DAX® -4,93 % -11,98 % -3,49 %
iShares Nasdaq 100 -2,63 % -2,22 % 13,78 %
iShares Nikkei 225® -4,73 % -10,90 % 19,71 %
iShares S&P 500 -2,54 % -3,54 % 8,88 %

Comments by Morgan_Stanley for this prediction

In the thread Celldex Therapeutics diskutieren
Prediction Buy
Perf. (%) 42.39%
Target price 42.182
Change
Ends at 20.03.26

Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $46.00 price target on the stock.
Ratings data for CLDX provided by MarketBeat

In the thread Trading Celldex Therapeutics
Prediction Buy
Perf. (%) 42.39%
Target price 42.182
Change
Ends at 20.03.26

Die von Morgan_Stanley gewählte maximale Laufzeit wurde überschritten

Current prediction by Morgan_Stanley for Celldex Therapeutics

buy
Celldex Therapeutics

Start price
Target price
Perf. (%)
€16.30
09.05.25
€38.34
09.05.26
69.33%
08:31